Aquestive Therapeutics Inc (AQST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,573 | -12,828 | -7,870 | 241 | 2,276 |
| Depreciation Amortization | 5,754 | 2,880 | 3,317 | 1,052 | 729 |
| Accounts receivable | 2,486 | 147 | -3,073 | -3,177 | -4,728 |
| Other Working Capital | -10,409 | -2,048 | -5,341 | -4,241 | -2,804 |
| Other Operating Activity | 352 | 1,465 | 6,587 | 4,687 | 5,436 |
| Operating Cash Flow | $-17,390 | $-10,384 | $-6,380 | $-1,438 | $909 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -64 | -29 | -995 | -979 | -828 |
| Investing Cash Flow | $-64 | $-29 | $-995 | $-979 | $-828 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 31,144 | N/A | N/A |
| Debt Repayment | -10 | -5 | -53,631 | -13,575 | -13,570 |
| Common Stock Issued | 84,360 | 82,639 | 17,259 | 13,647 | 8,663 |
| Other Financing Activity | -898 | -893 | 9,202 | -11 | -11 |
| Financing Cash Flow | $83,452 | $81,741 | $3,974 | $61 | $-4,918 |
| Beginning Cash Position | 23,872 | 23,872 | 27,273 | 27,273 | 27,273 |
| End Cash Position | 89,870 | 95,200 | 23,872 | 24,917 | 22,436 |
| Net Cash Flow | $65,998 | $71,328 | $-3,401 | $-2,356 | $-4,837 |
| Free Cash Flow | |||||
| Operating Cash Flow | -17,390 | -10,384 | -6,380 | -1,438 | 909 |
| Capital Expenditure | -64 | -29 | -995 | -979 | -828 |
| Free Cash Flow | -17,454 | -10,413 | -7,375 | -2,417 | 81 |